(Q34457045)

English

How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV. (English)

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

prevention of HIV/AIDS

0 references

Chaitra Gopalappa

object named as

Chaitra Gopalappa

5

0 references

8

object named as

Julio Montaner

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Timothy B Hallett

2

object named as

Timothy B Hallett

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

author name string

John Stover

1

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Zunyou Wu

3

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Mitchell Warren

4

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Carel Pretorius

6

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Peter D Ghys

7

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

Bernhard Schwartländer

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

New Prevention Technology Study Group

10

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

language of work or name

0 references

publication date

5 November 2014

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

e111956

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

copyright license

Creative Commons Attribution 4.0 International

5 November 2014

1 reference

April 2022 Public Data File from Crossref

copyright status

0 references

Using modeling to inform international guidelines for antiretroviral treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Elimination of HIV in South Africa through expanded access to antiretroviral therapy: a model comparison study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

HIV treatment as prevention: systematic comparison of mathematical models of the potential impact of antiretroviral therapy on HIV incidence in South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

The evolving landscape of the economics of HIV treatment and prevention

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Prevention of HIV-1 infection with early antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Treatment as prevention--a double hat-trick

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

HIV, transmitted drug resistance, and the paradox of preexposure prophylaxis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

The impact of an AIDS vaccine in developing countries: a new model and initial results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4221192

6 July 2018

Towards an improved investment approach for an effective response to HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0111956

21 January 2018

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PONE.0111956

21 January 2018

Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models

1 reference

https://pubmed.ncbi.nlm.nih.gov/25372770

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PONE.0111956

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

2014PLoSO...9k1956S

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

2 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34457045&oldid=1859736720"